Efficacy of gefitinib combined with bevacizumab versus gefitinib in advanced EGFR L858R NSCLC.

被引：0
|
作者：
Zhao, Xinmin
Wu, Xianghua
Wang, Huijie
Yu, Hui
Sun, Si
Feng, Yu
Wang, Jialei
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21185
引用
收藏
页数：3
相关论文
共 50 条
  • [41] High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study
    Li, X.
    Zhang, L.
    Jiang, D.
    Wang, Y.
    Zang, A.
    Ding, C.
    Zhao, M.
    Su, W.
    Zhang, Y.
    Zhong, D.
    Wu, J.
    An, G.
    Zhang, C.
    Hu, X.
    Cheng, G.
    Wang, H.
    Han, Z.
    He, X.
    Liu, J.
    Liang, L.
    Zhang, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1049 - S1049
  • [42] Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas
    Daisuke Akahori
    Yusuke Inoue
    Naoki Inui
    Masato Karayama
    Hideki Yasui
    Hironao Hozumi
    Yuzo Suzuki
    Kazuki Furuhashi
    Tomoyuki Fujisawa
    Noriyuki Enomoto
    Yutaro Nakamura
    Takafumi Suda
    [J]. Scientific Reports, 11
  • [43] Compound A, a fourth-generation allosteric inhibitor, a potent and highly selective EGFR with L858R activating and C797S resistance mutations for the treatment of NSCLC.
    Byeon, Yeji
    Jung, Seung Hee
    Yoon, Daseul
    Kang, Seock Yong
    Park, Jiyeon
    Jo, Hyeim
    Choi, Seong-Il
    Park, Somyi
    Lee, Seung-Chul
    Tae, Yang Hun
    Kim, Tae Min
    Cho, Sung-Yup
    Kim, Soyeon
    Ko, Donghyun
    Kim, Dong-Kyu
    Kim, Dong-Wan
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [44] Efficacy of pemetrexed for EGFR mutated lung carcinoma between L858R and Exon 19 deletion.
    Kogure, Yoshihito
    Saka, Hideo
    Oki, Masahide
    Kitagawa, Chiyoe
    Nakahata, Masashi
    Tsuboi, Rie
    Oka, Saori
    Hori, Kazumi
    Murakami, Yasushi
    Ise, Yuko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis
    Li, Z.
    Lu, J.
    Zhao, Y.
    Guo, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).
    Lu, Shun
    Dong, Xiaorong
    Jian, Hong
    Chen, Jianhua
    Chen, Gongyan
    Sun, Yuping
    Ji, Yinghua
    Wang, Ziping
    Shi, Jianhua
    Lu, Junguo
    Chen, Shaoshui
    Zhang, Guojun
    Lv, Dongqing
    Liu, Chunling
    Li, Juan
    Yu, Xinmin
    Lin, Zhong
    Yu, Zhuang
    Wang, Zhehai
    Cui, Jiuwei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Phase III Study Comparing Gefitinib (G) to Gefitinib Combined with Carboplatin and Pemetrexed (GCP) for NSCLC with EGFR Mutations (NEJ009)
    Fukuhara, T.
    Inoue, A.
    Morita, S.
    Sugawara, S.
    Hosomi, Y.
    Ikeda, S.
    Gemma, A.
    Takahashi, K.
    Fujita, Y.
    Harada, T.
    Minato, K.
    Takamura, K.
    Kobayashi, K.
    Nukiwa, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S467 - S467
  • [48] Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study
    Dai, Lili
    Wang, Wei
    Li, Wenli
    Wu, Ya
    Qu, Kaixin
    [J]. INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2022, 15 : 637 - 644
  • [49] PS 2 Patients with Advanced EGFR Mutant NSCLC: Subset Analysis of a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy
    Prabhash, K.
    Noronha, V.
    Patil, V.
    Joshi, A.
    Chougule, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S395 - S395
  • [50] Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR plus NSCLC in Japanese Patients (ARCHER 1050)
    Nakagawa, K.
    Ohyanagi, F.
    Kato, T.
    Takahashi, T.
    Kaneda, H.
    Nogami, N.
    Niho, S.
    Yamamoto, N.
    Fujita, Y.
    Zhang, H.
    Sbar, E.
    Wang, H.
    Linke, R.
    Tsuji, F.
    Mok, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2229 - S2230
12345